The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS
Amer Zeidan, MBBS, Yale University, New Haven, CT, shares the results of the Phase III IMerge study (NCT02598661) evaluating imetelstat in patients with lower-risk myelodysplastic syndromes (MDS). The trial reported promising results in terms of transfusion independence (TI) rate, durability of response, and disease modification. In addition, side effects including cytopenia were manageable and reversible with dose modifications. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, AbbVie, Takeda, Novartis, Aprea, Amgen, Otsuka, Gilead, Kura, Loxo Oncology, Geron, Mendus, Tyme: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees.
